A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps

Trial Profile

A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Mepolizumab (Primary) ; Mometasone
  • Indications Nasal polyps
  • Focus Registrational; Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors GlaxoSmithKline Research & Development
  • Most Recent Events

    • 03 May 2018 Planned End Date changed from 2 Aug 2019 to 26 Dec 2019.
    • 03 May 2018 Planned primary completion date changed from 2 Aug 2019 to 26 Dec 2019.
    • 18 Jan 2018 Planned End Date changed from 20 Jun 2019 to 2 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top